MetaVia Inc.MTVA
What MetaVia Inc. does.
We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and obesity.
● Vanoglipel (DA-1241) is a novel GPR119 (“GPR119”) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (“ T2DM”). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (“ GLP-1”), glucagon-dependent insulinotropic polypeptide receptor (“GIP”), and peptide YY (“PYY”) . These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel (DA-1241) has demonstrated beneficial effects on glucose, lipid profile and liver inflammation, as demonstrated during in-vivo preclinical studies.
o In Phase 1a and 1b human clinical trials, vanoglipel (DA-1241) was well tolerated in both healthy volunteers and those with T2DM.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$29.7M | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| Free cash flow | -$10.8M | -$15.1M | — | -$10.8M | -$24.7M | -$15.7M |
More on MTVA.
- MetaVia Inc. summary
- MetaVia Inc. financial statements
- MetaVia Inc. key metrics
- MetaVia Inc. health scores and style box
- MetaVia Inc. earnings
- MetaVia Inc. dividends
- MetaVia Inc. valuation
- MetaVia Inc. ownership and insiders
- MetaVia Inc. peers
Figures from MetaVia Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.